Relations between combined oral contraceptive therapy and indices of autonomic balance (baroreflex sensitivity and heart rate variability) in young healthy women

Ginekologia Polska

Volumn 84, Issue 11, 2013, Pages 915-921

  Wilczak, Anna ^a   Marciniak, Katarzyna ^a   Kłapciński, Michał ^a   Rydlewska, Agnieszka ^b,c   Danel, Dariusz ^d   Jankowska, Ewa A ^b,c,d  

^a 4TH MILITARY HOSPITAL   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c MILITARY HOSPITAL   (Poland)

^d Polish Academy of Sciences   (Poland)

Author keywords

Autonomic nervous system; Baroreflex sensitivity; Cardiovascular reflex regulation; Combined oral contraceptives; Heart rate variability

Indexed keywords

EID: 84893197080     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1660     Document Type: Article

References (61)

1. Minson C, Halliwill J, Young T, [et al.]. Influence of the menstrual cycle on sympathetic activity, baroreflex sensitivity, and vascular transduction in young women. Circulation. 2000, 101, 862-868.
2. Yildirir A, Kabakci G, Akgul E, et al.. Effects of menstrual cycle on cardiac autonomic innervations as assessed by heart rate variability. An Noninvasive Electrocardiol. 2002, 7, 60-63.
3. Goldman R, Azar A, Mulvaney J, et al.. Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids. Am J Physiol Regul Integr Comp Physiol. 2009, 296, 1419-1426.
4. Lobo R, Stanczyk F. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994, 170, 1499-1507.
5. Schleussner E, Brueckner T, Brautigam J, et al.. Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion. Gynecol Endocrinol. 2001, 15, 259-264.
6. Vandever M, Kuehl T, Sulak P, et al.. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008, 77, 162-170.
7. Sidhu J, Job S, Singh S, et al.. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006, 61, 191-199.
8. Mishell D Jr, Thorneycroft I, Nakamura R, et al.. Serum estradiol in women ingesting combination oral contraceptive steroids. Am J Obstet Gynecol. 1972, 114, 923-928.
9. Gaspard U, Romus M, Gillain D, et al.. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception. 1983, 27, 577-590.
10. Cianci A, De Leo V. Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives. Minerva Ginecol. 2007, 59, 415-425.
11. Aitken R, Baker M, Doncel G, et al.. As the world grows: contraception in the 21st century. J Clin Invest. 2008, 118, 1330-1343.
12. Silver Thorn D. Regulation of blood pressure. In: Human Physiology. Ed. Silver Thorn D. Benjamin Cummings, 2001, 462-466.
13. Du XJ, Riemersma R, Dart A. Cardiovascular protection by oestrogen is partly mediated through modulation of autonomic nervous function. Cardiovasc Res. 1995, 30, 161-165.
14. Dart A, Du XJ, Kingwell B. Gender, sex hormones and autonomic nervous control of the cardiovascular system. Cardiovasc Res. 2002, 53, 678-687.
15. Rydlewska A, Ponikowska B, Borodulin-Nadzieja L, et al.. Assessment of the functioning of autonomic nervous system in the context of cardiorespiratory reflex control. Kardiol Pol. 2010, 68, 951-957.
16. Leicht A, Hirning D, Allen G. Heart rate variability and endogenous sex hormones during the menstrual cycle in young women. Exp Physiol. 2003, 88, 441-446.
17. Camm A, Malik M, Bigger J, et al.. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the American Society of Pacing Electrophysiology. Circulation. 1996, 93, 1043-1065.
18. Mussalo H, Vanninen E, Ikäheimo R, et al.. Short-term blood pressure variability in renovascular hypertension and in severe and mild essential hypertension. Clin Sci. 2003, 105, 609-614.
19. Davies L, Francis D, Scott A, et al.. Effect of altering conditions of the sequence method on baroreflex sensitivity. J Hypertens. 2001, 19, 1279-1287.
20. Lanfranchi P, Somers V. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol. 2002, 283, 815-826.
21. Lipman R, Salisbury J, Taylor J. Spontaneous indices are inconsistent with arterial baroreflex gain. Hypertension. 2003, 42, 481-487.
22. Rydlewska A, Jankowska E, Ponikowska B, et al.. Changes in autonomic balance in patients with decompensated chronic heart failure. Clin Auton Res. 2011, 21, 47-54.
23. Collins P, Webb C. Estrogen hits the surface. Nat Med. 1999, 5, 1130-1131.
24. Wellman G, Bonev A, Nelson M, et al.. Gender differences in coronary artery diameter involve estrogen, nitric oxide, and Ca (2+)-dependent K+ channels. Circ Res. 1996, 79, 1024-1030.
25. Saleh T, Connell B. 17Beta-estradiol modulates baroreflex sensitivity and autonomic tone of female rats. J Auton Nerv Syst. 2000, 80, 148-161.
26. Saleh T, Connell B, Saleh M. Acute injection of 17beta-estradiol enhances cardiovascular reflexes and autonomic tone in ovariectomized female rats. Auton Neurosci. 2000, 84, 78-88.
27. Artero A, Tarín J, Cano A. The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Semin Thromb Hemost. 2012, 38, 797-807.
28. Veljković M, Popovć J. Venous thromboembolism and oral contraception. Med Pregl. 2010, 63, 376-379.
29. Jick S, Kaye J, Russmann S, et al.. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006, 73, 566-570.
30. Grady D, Wenger N, Herrington D, et al.. Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study. Obstet Gynecol Surv. 2000, 55, 699-702.
31. Hylckama Vlieg A, Helmerhorst F, Vandenbroucke J, et al.. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA casecontrol study. BMJ. 2009, 339, 2921.
32. Lizarelli P, Martins W, Vieira C, et al.. Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception. 2009, 79, 35-40.
33. Godsland F, Crook D, Simpson R, et al.. The Effects of Different Formulations of Oral Contraceptive Agents on Lipid and Carbohydrate Metabolism. N Engl J Med. 1990, 11, 1375-1381.
34. Berenson A, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. Obstet Gynecol. 2009, 114, 786-794.
35. Szlendak-Sauer K, Radowicki S, Skórzewska K, et al.. The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function. Ginekol Pol. 2009, 80, 99-102.
36. Broughton Pipkin F, Roberts J. Hypertension in pregnancy. J Hum Hypertens. 2000, 14, 705- 724.
37. Masilamani S, Heesch C. Effects of pregnancy and progesterone metabolites on arterial baroreflex in conscious rats. Am J Physiol. 1997, 272, R924-934.
38. Heesch C, Foley C. CNS effects of ovarian hormones and metabolites on neural control of circulation. Ann N Y Acad Sci. 2001, 940, 348-360.
39. Kvochina L, Hasser E, Heesch C. Pregnancy increases baroreflex-independent GABAergic inhibition of the RVLM in rats. Am J Physiol Regul Integr Comp Physiol. 2007, 293, R2295-2305.
40. Freeman E, Frye C, Rickels K, et al.. Allopregnanolone Levels and Symptom Improvement in Severe Premenstrual Syndrome. J ClinPsychopharmacol. 2002, 22, 516-520.
41. Bäckström T, Andréen L, Björn I, et al.. The role of progesterone and GABA in PMS/PMDD. The Premenstrual Syndromes: PMS and PMDD. 2007, 10, 117-120.
42. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychomat Res. 1993, 3, 195-202.
43. Honzíková N, Fiser B. Baroreflex sensitivity and essential hypertension in adolescents. Physiol Res. 2009, 58, 605-612.
44. La Rovere M, Bigger J, Marcus F, et al.. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998, 351, 478-484.
45. Hohage H, Gerhardt U. Variability of blood pressure and baroreceptor function; clinical and scientific relevance. Med Klin (Munich). 2000, 95, 254-260.
46. Iellamo F, Legramante JM, Massaro M, et al.. Effects of a Residential Exercise Training on Baroreflex Sensitivity and Heart Rate Variability in Patients With Coronary Artery Disease. Circulation. 2000, 102, 2588-2592.
47. Minson C, Halliwill J, Young T, et al.. Sympathetic Activity and Baroreflex Sensitivity in Young Women Taking Oral Contraceptives. Circulation. 2000, 102, 1473-1476.
48. Pitzalis M, Mastropasqua F, Passantino A, et al.. Comparison Between Noninvasive Indices of Baroreceptor Sensitivity and the Phenylephrine Method in Post-Myocardial Infarction Patients. Circulation. 1998, 97, 1362-1367.
49. Maestri R, Raczak G, Torunski A, et al.. Day-by-day variability of spontaneous baroreflex sensitivity measurements: implications for their reliability in clinical and research applications. J Hypertens. 2009, 27, 806-812.
50. Tzeng Y, Sin P, Lucas S, et al.. Respiratory modulation of cardiovagal baroreflex sensitivity. J Appl Physiol. 2009, 107, 718-724.
51. Radaelli A, Raco R, Perfetti P, et al.. Effects of slow, controlled breathing on baroreceptor control of heart rate and blood pressure in healthy men. J Hypertens. 2004, 22, 1361-1370.
52. Davies L, Francis D, Jurák P, et al.. Reproducibility of methods for assessing baroreflex sensitivity in normal controls and in patients with chronic heart failure. Clin Sci (Colch). 1999, 97, 515-522.
53. Souza H, De Araújo J, Martins-Pinge M, et al.. Nitric oxide synthesis blockade reduced the baroreflex sensitivity in trained rats. Auton Neurosci. 2009, 50, 38-44.
54. Merki-Feld G. Effect of combined hormonal contraceptives on the vascular endothelium und new cardiovascular risk parameters. Ther Umsch. 2009, 66, 89-92.
55. Simula S, Laitinen T, Vanninen E, et al.. Baroreflex sensitivity in asymptomatic coronary atherosclerosis. Clin Physiol Funct Imaging. 2013, 33, 70-74.
56. Rebelo A, Tamburús N, Salviati M, et al.. Influence of third-generation oral contraceptives on the complexity analysis and symbolic dynamics of heart rate variability. Eur J Contracept Reprod Health Care. 2011, 16, 289-297.
57. Deslypere J, Verdonck L, Vermeulen A. Fat Tissue: A Steroid Reservoir and Site of Steroid Metabolism. J Clin Endocrinol Metab. 1985, 61, 564-570.
58. Isidori A, Strollo F, Morè M, et al.. Leptin and Aging: Correlation with Endocrine Changes in Male and Female Healthy Adult Populations of Different Body Weights. J Clin Endocrinol Metab. 2000, 85, 1954-1962.
59. Edelman A, Carlson N, Cherala G, et al.. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception. 2009, 80, 119-127.
60. Wang S, Zhang L, Wang X, et al.. Age dependency of heart rate variability, blood pressure variability and baroreflex sensitivity. J Gravit Physiol. 2000, 7, 145-146.
61. Kardos A, Watterich G, De Menezes R, et al.. Determinants of spontaneous baroreflex sensitivity in a healthy working population. Hypertension. 2001, 37, 911-916.